SCHEMBL6079926

SCHEMBL6079926

O=C(Nc1cccc2c(O)cc(C(=O)O)nc12)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
RAB9A P51151 1/20 0.55
KDR P35968 1/20 0.52
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
MAPT P10636 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
ALDH1A1 P00352 1/20 0.47
PKM P14618 2/20 0.47
GPR35 Q9HC97 1/20 0.46
GRIK1 P39086 1/20 0.46
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
KCNMA1 Q12791 2/20 0.45
HDAC1 Q13547 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080449 0.84 KDM4E (0.47) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL8151512 0.82 NR1H4 (0.57) GPR35
SCHEMBL6080091 0.81 TOP2A (0.41) NPC1CYP1A2CYP3A4CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL6080479 0.80 ACHE (0.45) RAB9AKMT2AMAPTTDP1GPR35
SCHEMBL6080279 0.78 KDM4E (0.49) MEN1KMT2AMAPTMAPK1
SCHEMBL17540900 0.78 KDR (0.65) NPC1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL8165031 0.77 CYSLTR2 (0.42) NPC1RAB9AKMT2AMAPTALDH1A1
SCHEMBL8165026 0.77 CYSLTR2 (0.55) MEN1KMT2AALDH1A1GPR35
Xanthurenate SCHEMBL29911018 0.77 KDM4E (0.59) CYP1A2CYP2D6CYP2C9CYP2C19RAB9A
Xanthurenate SCHEMBL29394132 0.77 KDM4E (0.59) CYP1A2CYP2D6CYP2C9CYP2C19RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL NPC1 1911/4885CYP1A2 117/4885CYP3A4 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.